Who Paid My Doc
Felix Chion Fong
General Practice Miami, FL Medical Doctor
NPI 1255379186 CMS profile 740857
9732 Sw 24Th St, Miami, FL 33165
General payments
$130
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$510,519
Through program year 2023, Felix Chion Fong of Miami, FL is reported in the CMS Open Payments database as having received $130 across 7 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $510,519 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 39th percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $17 | 1 | |
| 2022 | General | $47 | 2 | |
| 2021 | General | $28 | 2 | |
| 2020 | General | $17 | 1 | |
| 2019 | General | $21 | 1 |
Beside peers
- Felix Chion Fong
- General Practice median
- Middle half of General Practice
- National median
In program year 2025, general payments to Felix Chion Fong were reported at $0. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.
Show as a table
| Year | Felix Chion Fong | General Practice median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $21 | $107 | $37–$285 | $163 |
| 2020 | $17 | $75 | $25–$213 | $114 |
| 2021 | $28 | $93 | $30–$272 | $132 |
| 2022 | $47 | $103 | $36–$279 | $149 |
| 2023 | $17 | $106 | $34–$276 | $160 |
| 2024 | $0 | $114 | $39–$290 | $164 |
| 2025 | $0 | $106 | $35–$292 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 136 drugsPart D claims
7,839
Drug cost
$198,263
Branded share of claims
17.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Januvia Sitagliptin Phosphate | Brand | 58 | $36,636 | |
| Farxiga Dapagliflozin Propanediol | Brand | 21 | $12,734 | |
| Eliquis Apixaban | Brand | 22 | $10,859 | |
| Linzess Linaclotide | Brand | 17 | $8,988 | |
| Tresiba Flextouch U-100 Insulin Degludec | Brand | 15 | $7,156 | |
| Xarelto Rivaroxaban | Brand | 11 | $7,136 | |
| Tradjenta Linagliptin | Brand | 13 | $6,603 | |
| Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog | Brand | 17 | $6,059 | |
| Vascepa Icosapent Ethyl | Brand | 23 | $5,657 | |
| Brilinta Ticagrelor | Brand | 11 | $5,315 |
The 10 drugs with the highest cost, of 136 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,210 Part D prescribers listed as General Practice; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 27 billing codesPaid by Medicare
$35,383
Medicare patients
79
Services billed
405
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 70% | |
| Chronic kidney disease | 68% | |
| Depression | 57% | |
| Diabetes | 53% | |
| Alzheimer's or dementia | 39% | |
| Ischemic heart disease | 38% | |
| COPD | 37% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
7 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
General Practice in Florida
Practitioners in the same specialty and state, ranked by reported value.
All General Practice
Everyone recorded under this specialty, nationwide.
Doctors in Florida
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.